Medical application of herpes simplex virus

Journal of Dermatological Science

Volumn 57, Issue 2, 2010, Pages 75-82

  Watanabe, Daisuke ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Amplicon vector; Herpes simplex virus; HSV; Medical application; Oncolytic virotherapy; Vaccine vector

Indexed keywords

D 106; D15 29; G 207; GLYCOPROTEIN D; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HERPES SIMPLEX VACCINE; HF 10; HSV 1716; MAC 239; NV 1020; ONCOLYTIC HERPES VIRUS; ONCOLYTIC VIRUS; ONCOVEX; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADVANCED CANCER; AMPLICON; ANTINEOPLASTIC ACTIVITY; BACTERIAL ARTIFICIAL CHROMOSOME; BREAST CANCER; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EYE DISEASE; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE STRUCTURE; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; LIVER METASTASIS; LOW DRUG DOSE; MELANOMA; NEOPLASM; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; RECURRENT CANCER; REPLICON; REVIEW; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; UNSPECIFIED SIDE EFFECT; VACCINE PRODUCTION; VIRAL GENE DELIVERY SYSTEM; VIREMIA; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS MORPHOLOGY; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS RECOMBINATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; BIOLOGICAL THERAPY; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; GENETIC VECTORS; HUMANS; MUTATION; ONCOLYTIC VIROTHERAPY; SIMPLEXVIRUS; VACCINES; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 74749094450     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2009.10.014     Document Type: Review

References (57)

1. Nishiyama Y. Herpes simplex virus gene products: the accessories reflect her lifestyle well. Rev Med Virol 14 (2004) 33-46
2. Witt M.N., Braun G.S., Ihrler S., and Schmid H. Occurrence of HSV-1-induced pneumonitis in patients under standard immunosuppressive therapy for rheumatic, vasculitic, and connective tissue disease. BMC Pulm Med 18 9 (2009) 22
3. McGeoch D.J., Dalrymple M.A., Davison A.J., Dolan A., Frame M.C., McNab D., et al. The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1. J Gen Virol 69 (1988) 1531-1574
4. Mori I., and Nishiyama Y. Herpes simplex virus and varicella-zoster virus: why do these human alphaherpes viruses behave so differently from one another?. Rev Med Virol 15 (2005) 393-406
5. Taylor T.J., Brockman M.A., McNamee E.E., and Knipe D.M. Herpes simplex virus. Front Biosci 7 (2002) d752-d764
6. Nishiyama Y. Herpesvirus genes: molecular basis of viral replication and pathogenicity. Nagoya J Med Sci 59 (1996) 107-119
7. Mori I., and Nishiyama Y. Accessory genes define the relationship between the herpes simplex virus and its host. Microb Infect 8 (2006) 2556-2562
8. Marconi P., Argnani R., Berto E., Epstein A.L., and Manservigi R. HSV as a vector in vaccine development and gene therapy. Hum Vaccine 4 (2008) 91-105
9. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 13 (2008) 2060-2064
10. Bataille D., and Epstein A.L. Herpes simplex virus type 1 replication and recombination. Biochimie 77 (1995) 787-795
11. Kong Y., Yang T., and Geller A.I. An efficient in vivo recombination cloning procedure for modifying and combining HSV-1 cosmids. J Virol Methods 80 (1999) 129-136
12. Stavropoulos T.A., and Strathdee C.A. An enhanced packaging system for helper-dependent herpes simplex virus vectors. J Virol 72 (1998) 7137-7143
13. Tanaka M., Kagawa H., Yamanashi Y., Sata T., and Kawaguchi Y. Construction of an excisable bacterial artificial chromosome containing a full-length infectious clone of herpes simplex virus type 1: viruses reconstituted from the clone exhibit wild-type properties in vitro and in vivo. J Virol 77 (2003) 1382-1391
14. Shah K., and Breakefield X.O. HSV amplicon vectors for cancer therapy. Curr Gene Ther 6 (2006) 361-370
15. Epstein A.L. HSV-1-based amplicon vectors: design and applications. Gene Ther 12 (2005) S154-S158
16. Frenkel N. The history of the HSV amplicon: from naturally occurring defective genomes to engineered amplicon vectors. Curr Gene Ther 6 (2006) 277-301
17. Cuchet D., Potel C., Thomas J., and Epstein A.L. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther 7 (2007) 975-995
18. Kasai K., and Saeki Y. DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr Gene Ther 6 (2006) 303-314
19. Brooks A.I., Cory-Slechta D.A., Bowers W.J., Murg S.L., and Federoff H.J. Enhanced learning in mice parallels vector-mediated nerve growth factor expression in hippocampus. Hum Gene Ther 11 (2000) 2341-2352
20. Harvey B.K., Chang C.F., Chiang Y.H., Bowers W.J., Morales M., Hoffer B.J., et al. HSV amplicon delivery of glial cell line-derived neurotrophic factor is neuroprotective against ischemic injury. Exp Neurol 183 (2003) 47-55
21. Costantini L.C., Jacoby D.R., Wang S., Fraefel C., Breakefield X.O., and Isacson O. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors. Hum Gene Ther 10 (1999) 2481-2494
22. Lim F., Palomo G.M., Mauritz C., Giménez-Cassina A., Illana B., Wandosell F., et al. Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol Ther 15 (2007) 1072-1078
23. Santos K., Duke C.M., and Dewhurst S. Amplicons as vaccine vectors. Curr Gene Ther 6 (2006) 383-392
24. Fraefel C. Gene delivery using helper virus-free HSV-1 amplicon vectors. Curr Protoc Neurosci (2007) [Chapter 4:Unit 4.14]
25. McLean C.S., Ni Challanáin D., Duncan I., Boursnell M.E., Jennings R., and Inglis S.C. Induction of a protective immune response by mucosal vaccination with a DISC HSV-1 vaccine. Vaccine 14 July (1996) 987-992
26. Da Costa X., Kramer M.F., Zhu J., Brockman M.A., and Knipe D.M. Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2. J Virol 74 (2000) 7963-7971
27. Jones C.A., Taylor T.J., and Knipe D.M. Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model. Virology 278 (2000) 137-150
28. van Lint A.L., Torres-Lopez E., and Knipe D.M. Immunization with a replication-defective herpes simplex virus 2 mutant reduces herpes simplex virus 1 infection and prevents ocular disease. Virology 368 (2007) 227-231
29. Hoshino Y., Dalai S.K., Wang K., Pesnicak L., Lau T.Y., Knipe D.M., et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J Virol 79 (2005) 410-418
30. Spencer C.A., Dahmus M.E., and Rice S.A. Repression of host RNA polymerase II transcription by herpes simplex virus type 1. J Virol 71 (1997) 2031-2040
31. Smiley J.R. Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?. J Virol 78 (2004) 1063-1068
32. Song B., Yeh K.C., Liu J.J., and Knipe D.M. Herpes simplex virus gene roducts required for viral infection of expression of G1-phase functions. Virology 290 (2001) 320-328
33. Samaniego L.A., Wu N., and DeLuca N.A. The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. J Virol 71 (1997) 4614-4625
34. Samaniego L.A., Neiderhiser L., and DeLuca N.A. Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. J Virol 72 (1998) 3307-3320
35. Watanabe D., Brockman M.A., Ndung'u T., Mathews L., Lucas W.T., Murphy C.G., et al. Properties of a herpes simplex virus multiple immediate-early gene-deleted recombinant as a vaccine vector. Virology 357 (2007) 186-198
36. Kaur A., Sanford H.B., Garry D., Lang S., Klumpp S.A., Watanabe D., et al. Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus. Virology 357 (2007) 199-214
37. Liu X., Broberg E., Watanabe D., Dudek T., Deluca N., and Knipe D.M. Genetic engineering of a modified herpes simplex virus 1 vaccine vector. Vaccine 27 (2009) 2760-2767
38. Lauterbach H., Kerksiek K.M., Busch D.H., Berto E., Bozac A., Mavromara P., et al. Protection from bacterial infection by a single vaccination with replication-deficient mutant herpes simplex virus type 1. J Virol 78 (2004) 4020-4028
39. Glorioso J.C., and Fink D.J. Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther 17 (2009) 13-18
40. Davis J.J., and Fang B. Oncolytic virotherapy for cancer treatment: challenges and solutions. J Gene Med 7 (2005) 1380-1389
41. Advani S.J., Mezhir J.J., Roizman B., and Weichselbaum R.R. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66 (2006) 637-646
42. Sarinella F., Calistri A., Sette P., Palù G., and Parolin C. Oncolysis of pancreatic tumour cells by a gamma34.5-deleted HSV-1 does not rely upon Ras-activation, but on the PI 3-kinase pathway. Gene Ther 13 (2006) 1080-1087
43. Harrow S., Papanastassiou V., Harland J., Mabbs R., Petty R., Fraser M., et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11 (2004) 1648-1658
44. MacKie R.M., Stewart B., and Brown S.M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 357 (2001) 525-526
45. Markert J.M., Medlock M.D., Rabkin S.D., Gillespie G.Y., Todo T., Hunter W.D., et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7 May (10) (2000) 867-874
46. Kemeny N., Brown K., Covey A., Kim T., Bhargava A., Brody L., et al. Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther 17 (2006) 1214-1224
47. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12 (2006) 6737-6747
48. Nishiyama Y., Kimura H., and Daikoku T. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J Virol 65 (1991) 4520-4524
49. Ushijima Y., Luo C., Goshima F., Yamauchi Y., Kimura H., and Nishiyama Y. Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microb Infect 9 (2007) 142-149
50. Koshizuka T., Kawaguchi Y., and Nishiyama Y. Herpes simplex virus type 2 membrane protein UL56 associates with the kinesin motor protein KIF1A. J Gen Virol 86 (2005) 527-533
51. Jones C., Inman M., Peng W., Henderson G., Doster A., Perng G.C., et al. The herpes simplex virus type 1 locus that encodes the latency-associated transcript enhances the frequency of encephalitis in male BALB/c mice. J Virol 79 (2005) 14465-14469
52. Nawa A., Luo C., Zhang L., Ushjima Y., Ishida D., Kamakura M., et al. Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: applications for cancer gene therapy. Curr Gene Ther 8 (2008) 208-221
53. Takakuwa H., Goshima F., Nozawa N., Yoshikawa T., Kimata H., Nakao A., et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 148 (2003) 813-825
54. Watanabe D., Goshima F., Mori I., Tamada Y., Matsumoto Y., and Nishiyama Y. Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10. J Dermatol Sci 50 (2008) 185-196
55. Kohno S.I., Luo C., Nawa A., Fujimoto Y., Watanabe D., Goshima F., et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther 14 (2007) 918-926
56. Kimata H., Imai T., Kikumori T., Teshigahara O., Nagasaka T., Goshima F., et al. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann Surg Oncol 13 (2006) 1078-1084
57. Fujimoto Y., Mizuno T., Sugiura S., Goshima F., Kohno S., Nakashima T., et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 126 (2006) 1115-1117